Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-cash Items (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Non-cash Items for 6 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 380.57% to $18.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.8 million, a 380.57% increase, with the full-year FY2025 number at $18.8 million, up 380.57% from a year prior.
  • Non-cash Items was $18.8 million for Q4 2025 at TScan Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $28.3 million in Q4 2023 to a low of $2.1 million in Q4 2021.
  • A 5-year average of $11.9 million and a median of $10.6 million in 2021 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: surged 513.21% in 2022, then crashed 86.17% in 2024.
  • TScan Therapeutics' Non-cash Items stood at $2.1 million in 2021, then soared by 513.21% to $13.0 million in 2022, then soared by 117.52% to $28.3 million in 2023, then plummeted by 86.17% to $3.9 million in 2024, then surged by 380.57% to $18.8 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Non-cash Items are $18.8 million (Q4 2025), $3.9 million (Q4 2024), and $28.3 million (Q4 2023).